L'Air Liquide S.A. (AIL)
XETRA Stock Exchange · Germany · prices in EUR · close of 22 Oct 2026
Key indicators
| Last close | EUR 173.70 |
|---|---|
| 52-week range | 155.00 – 189.76 |
| Return, 1 month / 3 months | +3.9% / −1.7% |
| Return, 1 year / 3 years | +13.3% / +45.7% |
| Trend | Uptrend |
| RSI (14) | 61 |
| Volatility (1 year) | 18.0% |
| Worst drawdown (1 year) | -10.6% |
| Average daily value traded | 0.22M EUR |
| Dividend yield | 2.1% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
L'Air Liquide is a French industrial gases company based in Paris. It produces gases such as oxygen, nitrogen, hydrogen and argon, along with specialty gases and related equipment and services. Its customers are mainly industrial firms in steel, chemicals, refining, electronics and manufacturing, and it also supplies medical gases and home healthcare services to hospitals and patients. The company operates plants and distribution networks in many countries, serving large industrial sites as well as smaller users of packaged gases.
L'Air Liquide S.A. trades under the code AIL on the XETRA Stock Exchange in Germany, with its price quoted in euros (EUR). Our dividend records, which start in 2019, show payments in 8 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
L'Air Liquide S.A. (AIL) trades on the XETRA Stock Exchange in Germany. It last closed at EUR 173.70 on 22 October 2026.
Its price-based Market X-Ray is 70 out of 100 (a fair price profile), ranking 112 of 701 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 13.3% and over the last three months it fell 1.7%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on XETRA Stock Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 71 · Strong | Trading above its long-term averages and near its highs. | |
| Above 200-day average | 6.7% | ||
| From 52-week high | -7.8% | ||
| Momentum | 59 · Fair | Typical recent returns for this exchange. | |
| 3-month return | -1.7% | ||
| 6-month return | 4.7% | ||
| 12-month return, skipping the last month | 9.0% | ||
| Stability (higher is calmer) | 97 · Strong | Calmer than most: low volatility and shallow drawdowns. | |
| Volatility, 1 year (lower is calmer) | 18.0% | ||
| Worst drawdown, 1 year (smaller is calmer) | -10.6% | ||
| Liquidity | 55 · Fair | Moderate trading activity. | |
| Average daily value traded | 0.22M EUR | ||
| Zero-volume days | 0.0% | ||
| Income | 46 · Weak | Dividend is small or irregular. | |
| Dividend yield | 2.1% | ||
| Years with dividends | 5 |
Strengths
- Trend: Trading above its long-term averages and near its highs.
- Stability (higher is calmer): Calmer than most: low volatility and shallow drawdowns.
Weak spots
- Income: Dividend is small or irregular.
Returns
| 1 week | +0.5% |
|---|---|
| 1 month | +3.9% |
| 3 months | −1.7% |
| 6 months | +4.7% |
| 1 year | +13.3% |
| 3 years | +45.7% |
| 5 years | +77.5% |
Signals
| 50-day / 200-day average | 168.99 / 162.82 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 2.28 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 18 May 2026 | EUR 3.7000 |
| 19 May 2025 | EUR 3.3000 |
| 20 May 2024 | EUR 3.2000 |
| 15 May 2023 | EUR 2.9500 |
| 16 May 2022 | EUR 2.9000 |
| 17 May 2021 | EUR 2.7500 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on XETRA Stock Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.